Craft

Vericel

Stock Price

$45.8

2024-10-29

Market Capitalization

$2.2 B

2024-10-29

Revenue

$237.2 M

FY, 2024

Vericel Summary

Company Summary

Overview
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The Company markets two cell therapy products in the United States. Carticel (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Type
Public
Status
Active
Founded
1989
HQ
Cambridge, MA, US | view all locations
Website
http://vcel.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Dominick Colangelo

    Dominick Colangelo, President and Chief Executive Officer, Director

    • Mike Halpin

      Mike Halpin, Chief Operating Officer

    • Joe Mara

      Joe Mara, Chief Financial Officer

      • Jonathan Hopper

        Jonathan Hopper, Chief Medical Officer

      Operating MetricsView all

      Phase II Trials Products

      1

      FY, 2016

      Approval Phase Products

      3

      FY, 2016

      LocationsView all

      2 locations detected

      • Cambridge, MA HQ

        United States

        64 Sidney St

      • Ann Arbor, MI

        United States

      Vericel Financials

      Summary Financials

      Revenue (Q1, 2025)
      $52.6M
      Gross profit (Q1, 2025)
      $36.3M
      Net income (Q1, 2025)
      ($11.2M)
      Cash (Q1, 2025)
      $73.5M
      EBIT (Q1, 2025)
      ($12.8M)
      Enterprise value
      $2.2B

      Footer menu